Navigation Links
CPAP treatment effective in patients with milder OSA and daytime sleepiness
Date:7/19/2012

Continuous positive airway pressure (CPAP), well established as an effective treatment for severe obstructive sleep apnea (OSA), is also effective in patients with mild and moderately severe OSA and daytime sleepiness, according to a new study.

"The evidence for the efficacy of CPAP in patients with milder OSA is limited and conflicting," said lead author Terri E. Weaver, PhD, RN, professor and dean of the University of Illinois at Chicago College of Nursing. "Our multi-site, double-blind, randomized trial, the first placebo-controlled study to use sham CPAP in sleepy patients with mild to moderate OSA, shows that CPAP treatment effectively reduces symptoms and improves quality of life in these patients, the largest segment of the OSA population."

The findings were published online ahead of print publication in the American Thoracic Society's American Journal of Respiratory and Critical Care Medicine.

In the study, 239 patients with newly diagnosed milder OSA and self-reported daytime sleepiness (an Epworth Sleepiness Scale (ESS) score > 10) were randomized to eight weeks of active or sham CPAP treatment. After the eight-week intervention, patients in the sham arm were crossed over to eight weeks of active treatment. The primary outcome measure was total score on the Functional Outcomes of Sleep Questionnaire (FOSQ), which measures the impact of daytime sleepiness on activities of daily living.

The adjusted mean change in FOSQ total score after the initial eight-week intervention was 0.89 for actively treated patients and -0.06 for sham-treated patients (p = 0.006). Mean improvement in FOSQ total score from the beginning to the end of the cross-over phase of the study was 1.73 2.50 (p <0.00001). Significant improvements with active treatment were also seen in ESS scores, Physical Component scores on the Short-Form 36 health survey, and Total Mood Disturbance scores on the Profile of Mood States scale.

"The improvements we saw were highly significant and clinically relevant," said Dr. Weaver. "In addition, our study was conducted at both large and smaller clinical practice sites, making our results highly generalizable."

The study had some limitations, including a short mean duration of active daily CPAP treatment (4.0 2.0 hours/day) and a lower mean duration of sham daily CPAP treatment (3.1 2.1 hours/day).

"Given the high prevalence of OSA, our study suggests that there is significant value in treating sleepy patients with mild to moderate disease," concluded Dr. Weaver. "CPAP therapy, the primary treatment for OSA, is highly effective and confers significant health benefits in these patients."


'/>"/>

Contact: Nathaniel Dunford
ndunford@thoracic.org
212-315-8620
American Thoracic Society
Source:Eurekalert

Related medicine news :

1. Scientist awarded $1 million grant to develop tools for hepatitis C treatment discovery
2. Clinical insight improves treatment with new lung cancer drug
3. Rapid Asthma Treatment in ER May Prevent Admission
4. Novel compound demonstrates anti-leukemic effect in zebrafish, shows promise for human treatment
5. Breast cancer patients suffer treatment-related side effects long after completing care
6. Mayo Clinic offers newly approved treatment for acid reflux disease
7. Mobile Stroke Units Might Trim Time to Treatment
8. Breast Cancer Treatment Side Effects May Last for Years
9. Mouse Study Hints at New Path for Diabetes Treatment
10. Symptomatic behaviour in childhood strongly predicts psychiatric treatment as a young adult
11. Exercise improves quality of life during breast cancer treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... 24, 2016 , ... June 19, 2016 is World Sickle Cell Observance Day. ... the benefits of holistic treatments, Serenity Recovery Center of Marne, Michigan, has ... , Sickle Cell Disease (SCD) is a disorder of the red blood cells, which ...
(Date:6/24/2016)... ... ... Global law firm Greenberg Traurig, P.A. announced that 20 Florida attorneys are ... for this recognition are considered among the top 2 percent of lawyers practicing within ... of this year’s Legal Elite Hall of Fame: Miami Shareholders Mark D. Bloom, ...
(Date:6/24/2016)... ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain ... for a minimum wage raise to $12 an hour by 2020 and then adjusting it ... the lost value of the minimum wage, assure the wage floor does not erode again, ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... to recognize Dr. Barry M. Weintraub as a prominent plastic surgeon and the ... in the world, and the most handsome men, look naturally attractive. Plastic surgery ...
(Date:6/24/2016)... ... ... National recruitment firm Slone Partners is pleased to announce the placement of ... President of North American Capital Sales at HTG Molecular . , ... the commercialization of the HTG EdgeSeq system and associated reagents in North America. , ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... 2016 , , , WHEN: ... 2016 , , , , LOCATION: , , , Online, ... , , EXPERT PANELISTS:  , , , Frost & Sullivan,s Global ... Bird; Senior Industry Analyst, Divyaa Ravishankar and Unmesh Lal, Program Manager ... pharmaceutical industry is witnessing an exceptional era. Several new demand spaces, ...
(Date:6/23/2016)... , June 23, 2016  Guerbet announced today ... Inc.,s Supplier Horizon Award . One ... Guerbet was recognized for its support of Premier members ... through clinical excellence, and commitment to lower costs. ... receive this recognition of our outstanding customer service from ...
(Date:6/23/2016)... The Biotechnology industry might still ... great opportunities to investors. Stock-Callers.com assesses the recent performances ... XON ), Vertex Pharmaceuticals Inc. (NASDAQ: ... ARNA ), and Regeneron Pharmaceuticals Inc. (NASDAQ: ... your complimentary trade alerts at: http://stock-callers.com/registration ...
Breaking Medicine Technology: